Q-omics provides the consensus-scored NIFKP4 profile across patient tissues and cancer cell-line models. NIFKP4 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NIFKP4 is differentially expressed in 1, with the highest sampling consensus in HNSC. Additionally, NIFKP4 RNA expression shows 6,466 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, HNSC, and STAD as cancer lineages where NIFKP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NIFKP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NIFKP4 survival associations across molecular data types. NIFKP4 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NIFKP4 RNA expression–survival associations across cancer types. High NIFKP4 expression shows unfavorable associations in MESO, KIRP, LUSC, DLBC and ESCA, but favorable associations in BRCA. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for NIFKP4 RNA expression.
This table summarizes NIFKP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for NIFKP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NIFKP4 shows higher tumor expression in HNSC. The HNSC box plot shows higher NIFKP4 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p < 0.001).
This table shows molecular features associated with NIFKP4 in patient tissues and cancer cell lines. In patient samples, NIFKP4 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
